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Anti-Mullerian Hormone is useful in examining folliculogenesis and ovarian abilities. Previous 
research found that follicular fluid and serum in PCOS women containing high AMH levels. As 
therapy in PCOS with insulin resistance, metformin, an insulin sensitizer agent can be given.  The 
efficacy of metformin therapy in inducing ovulation is more due to the local action of metformin 
on the ovaries rather than the systemic improvements that result both metabolically and 
hormonally.  We conducted this study to evaluate the levels of Anti-Mullerian Hormone (AMH) 
in women with polycystic ovarian syndrome (PCOS) with insulin resistance before and after 
metformin therapy. An analytic observational study with cross-sectional design. Seventy PCOS 
women with insulin resistance, taking metformin for 3 months, were enrolled in this study. Serum 
levels of AMH was assessed before and after treatment, and the difference between them was 
analyzed  with student t-test. Diagnosis of PCOS is made based on Rotterdam criteria and insulin 
resistance by HOMA-IR calculation. This study was conducted at the Fertility and Reproductive 
Endocrinology Polyclinic of Dr. Mohammad Hoesin Palembang hospital and Imaya clinic. The 
mean age of PCOS patients with insulin resistance ranges from 25-30 years, with a mean age of 
28.61±3.883.  The mean AMH levels prior metformin therapy was 7.6957±0.6001 ng/ml; mean 
AMH after therapy was 7.5914±0.57678 ng/ml; and there are significant differences (p <0.001).  
The mean AMH levels in all patients were 0.10429.  Based on body mass index (BMI), a total of 
52 respondents (74.29%) met the criteria for obesity and 18 respondents (25.71%)  nonobese.  
There is a relationship between AMH levels and the number of follicles (p <0.01), with an OR of 
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Polycystic Ovary Syndrome (PCOS) is 
an endocrine disorder that is often found in 
reproductive age women. The diagnosis of 
PCOS is based on the presence of 
hyperandrogenism and chronic anovulation 
with exclusion of specific conditions from 
the adrenal glands, ovaries, or pituitary. The 
prevalence of PCOS is between 5-10%. 1,2 
     The most probable mechanism of 
pathophysiology of PCOS is impaired 
dominant follicular selection resulting in 
anovulation. Impaired selection mechanism 
results in the accumulation of small antral 
follicles, which contribute significantly to the 
production of Anti-Mullerian Hormone 
(AMH). Anti-Mullerian Hormone decreases 
follicular sensitivity to FSH, causing 
impaired follicular selection. It is suspected 
that the aromatase activity of PCOS patients 
may decrease because the follicles in PCOS 
patients do not produce estrogen (E2) in large 
quantities. AMH also inhibits aromatase 
activity, so AMH is considered to affect the 
severity of PCOS. 3 
     Anti Mullerian Hormone is useful in 
examining folliculogenesis and ovarian 
abilities. Previous research found that 
follicular fluid and serum in PCOS women 
containing high AMH levels. Anti-Mullerian 
Hormone serum levels of PCOS are related to 
the antral follicles count. An increase of two 
to three times the number of developing 
follicles shows an increase of two to three 
times the level of serum AMH 3 
     PCOS is closely related to insulin 
resistance and hyperinsulinemia, which has 
been shown in several studies that obesity is 
also often found in PCOS. 3,4 Barbieri et al. 
concluded that insulin stimulates the 
production of androgen binding and invitro 
ovarian stroma. 5 
 
     The relationship of fasting insulin and free 
androgens supports the hypothesis that 
hyperinsulinemia can increase 
hyperandrogenemia in PCOS. 3 Insulin also 
suppresses levels of sex hormone binding 
globulin (SHBG), so that free androgen 
increases. Increased androgens will affect the 
ovarian environment to be androgenic, 
disruption of the androgen aromatization 
system to estrogen so that it triggers earlier 
follicular atresia. 6,7 Decreased levels of 
SHBG can be used as a single predictor in the 
identification of an increased risk of insulin 
resistance in nonobese PCOS. 8 
     Obesity in PCOS is a factor that affects the 
phenotype of this syndrome and worsens 
endocrine and metabolic parameters 
including insulin action. 8 Compared to 
normal women, obese and nonobese women 
with PCOS experience insulin resistance and 
hyperinsulinemia. 9 In a study conducted by 
Wiweko B and Mulya R at the RSCM stated 
that 75% of PCOS patients had insulin 
resistance and from 32 obese patients they 
found 84% had insulin resistance while only 
50% nonobese patients had insulin 
resistance. 10 Rusnasari (2005) obtained the 
frequency of insulin resistance using the 
Homeostasis Model Assessment (HOMA-
IR) method which is considered close to the 
Euglycemic clamp technique, the gold 
standard for predicting insulin resistance. 
With this method, insulin resistance of PCOS 
sufferers was 82.9%. 11 
     As therapy in PCOS with insulin 
resistance, metformin, an insulin sensitizer 
agent can be given. Palomba showed that 
administration of metformin had systemic 
influences by reducing hyperandrogenism in 
PCOS patients and also worked directly on 
the ovaries. The efficacy of metformin 
therapy in inducing ovulation is more due to 
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the local action of metformin on the ovaries 
rather than the systemic improvements that 
result both metabolically and hormonally.11,12 
This study aims to determine the effect of 
metformin therapy in PCOS patients in 





This study was an observational study 
with a cross sectional approach, which was 
conducted at the Reproductive 
Endocrinology Fertility Polyclinic in dr. 
Mohammad Hoesin General Hospital 
Palembang and Imaya Clinic, from February 
2015 until the number of samples were met. 
The number of samples needed was 70 
samples. The sample selection method used 
consecutive sampling. Inclusion criteria 
included reproductive age women who were 
diagnosed with PCOS and accompanied by 
insulin resistance, had no diabetes mellitus, 
and had no family history of diabetes 
mellitus. PCOS patients who were 
undergoing hormonal contraceptive therapy 
and did not adhere to the therapeutic schedule 
were excluded from the study. Insulin 
resistance (IR) was established based on the 
HOMA-IR method, namely: 
 
IR = fasting insulin (µUI/ml) x fasting 
glucose (mmol/ml) 
22.5 
                  
The normal value of insulin resistance 
according to Matthew was <1. Polycystic 
ovarian syndrome was diagnosed if it 
fulfilled 2 of the following 3 criterias, namely 
oligo or anovulation; clinical signs or 
symptoms of hyperandrogenism, including 
hirsutism and acne; and polycystic ovary 
features on transvaginal ultrasound or 
laparoscopy. Anti Mullerian Hormone was a 
member of transforming growth factor-b 
which could be examined from a patient's 
blood sample using an enzyme immunoassay 
(ELISA). The level of AMH serum in PCOS 
patients with insulin resistance were first 
examined before receiving metformin 
therapy, then re-examined after 3 months 
therapy. Normal level of AMH serum ranged 




From 70 samples, the mean age of the 
patients was 28.61 ± 3.883. The majority of 
patients was between 25-30 years namely 42 
respondents (60%). Based on body mass 
index (BMI), 52 respondents (74.29%) met 
the obesity criteria and 18 respondents were 
classified as nonobese (25.71%), where the 
lowest BMI was 19 and the highest BMI was 
33. Based on the length of the menstrual 
cycle, we obtained that 39 respondents 
experienced 30-60 days of menstrual cycles, 
while the fewest had menstrual cycles 60-90 
days. Based on the antral follicles count, 43 
respondents (61.4%) had more than 20 
follicles. The distribution of respondent 
characteristics can be seen in table 1. 
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Table 1. Distribution of respondent characteristics 
 
Characteristics Frequency Percentage (%) 
Age 
     25-30 
     30-35 










     Obese 
     Nonobese 










     30-60 days 
     60-90 days 
     90-120 days 











Antral follicle count 
     10-20 
     20-30 









The mean of AMH serum levels before and 
after metformin therapy were compared and 
tested with a student t-test. There were 
significant differences (p <0.001) on the 
mean of AMH levels before and after 
metformin therapy. The mean of 
pretreatment and post treatment AMH level 
were 7.6957±0.6001 and 7.5914±0.57678, 





Table 2. Comparison of AMH levels before and after receiving metformin therapy 
 
Variables Mean SD Min Max Delta mean P 
Pre-treatment AMH 7.6957 0.6001 6.3 9.2 0.10429 <0.001 
Post-treatment AMH 7.5914 0.57678 6.2 9.1   
A significant decrease in the average AMH 
level after metformin treatment was found in 
52 samples of obese group namely 0.05 (p = 
0.022), which showed that metformin was 
able to reduce AMH levels in obese PCOS 
patients significantly and effectively in the 
majority of cases (table 3).  A decrease in the 
average AMH levels after metformin 
treatment was found in 18 samples of 
nonobese group by 0.02778. The statistical 
calculation found that the reduction in AMH 
levels after metformin therapy was not 
significant (p = 0.384) (table 4).  
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Table 3. Comparison of AMH levels before and after metformin therapy in obese PCOS patients 
 
AMH Level 
(pre vs post 
treatment) 
AMH serum levels of obese PCOS 
patients 





N Mean Std. Deviation  
 




Pre treatment AMH 52 7.9231 0.51359 
Post treatment AMH 52 7.8731 0.43572      
 
 




(pre vs post 
treatment) 
AMH serum levels of nonobese PCOS 
patients 











Pre treatment AMH 18 7.0389 0.23549 
Post treatment AMH 18 7.0111 0.26544  
 
     To find out whether there is a decrease in 
AMH levels before and after metformin 
treatment in obese and nonobese PCOS 
patients, a student t-test was calculated. From 
table 5, it was known that the mean AMH 
level before metformin therapy in obese 
PCOS patients is 7.9231 ± 0.51359 and the 
mean AMH level before therapy in nonobese 
patients was 7.0389 ± 0.23549. There was a 
difference in the mean AMH level before 
metformin therapy in the obese group and 
nonobese group is 0.88419.  
     From table 6, the mean AMH level after 
metformin therapy in obese PCOS patients 
was 7.8731 ± 0.43572 and the mean AMH 
level after therapy in nonobese PCOS 
patients is 7.0111 ± 0.26544. There was 
difference in the mean AMH levels after 
metformin therapy in the obese group and 




Table 5. Comparison of AMH levels before metformin therapy 
 
BMI Category 
(obese vs non obese) 
Pretreatment AMH serum level ∆ Mean of AMH serum level  
p 






Obese 52 7.9231 0.51359 
Nonobese 18 7.0389 0.23549   
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Table 6. Comparison of AMH levels after metformin therapy 
 
BMI Category 
(obese vs non obese) 
Post treatment AMH serum 
level 









<0.001 Obese 52 7.8731 0.43572 
Nonobese 18 7.0111  0.26544  
 
Table 7. Differences of AMH levels in obese and non-obese PCOS patients 
 
BMI Category 
(obese vs non obese) 
Pretreatment -Post treatment 
AMH serum level 




N Mean Std. Deviation  
0.02222 
 
0.058 Obese 52 0.05 0.01527 
Non-Obese 18 0.0278 0.00131  
 
     From table 7, it is known that the delta 
mean of AMH levels in obese patients was 
0.05 ± 0.01527 and the delta mean of AMH 
levels in nonobese patients was 0.0278 ± 
0.00131. There was no significant difference 
(p> 0.05) between these two groups and the 




     Based on the chi square analysis (x2), 
there was no relationship between AMH 
level category and BMI category (p> 0.05) 
which could be seen in table 8. Spearman's 
correlation showed a weak negative 
correlation (r = -0,244), it could be seen in 
Image 1.  
 




Total P r 1.5 – 4 >4 
N % N % N % 
18.5-25 4 5.7 17 24.3 21 30 
0.423 -0.244  
25.1-27 3 4.3 17 24.3 20 28.6 
>27 2 2.9 27 38.6 29 41.4 
Total 9 12.9 61 87.1 70 100 
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The relationship between the categories of 
menstrual cycle length and AMH levels was 
shown in Table 9. Based on the chi square 
(x2) analysis, it was found that no relationship 
was found between the categories of AMH 
levels and menstrual periods (p> 0.05). 
Spearman's correlation showed a weak 
negative correlation (r = -0.112). 
 
 




AMH Category   
p r 1.5 – 4 >4 Total 
N % N % N % 
30 – 60 4 5.7 35 50 39 55.7 0.526 -0.112 
 
60 – 90  1 1.4 10 14.3 11 15.7   
90 – 120 4 5.7 16 22.9 20 28.6   
Total 9 12.9 61 87.1 70 100   
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      The relationship between categories of 
antral follicles count and AMH levels was 
calculated based on chi square (x2) analysis. 
It was found that there was a relationship 
between AMH levels and follicles count (p 
<0.01), with OR 1.5. Spearman's correlation 
showed a medium positive correlation (r = 
0.485), where the higher the AMH level of 
the patient, the number of follicles is 1.5 
times more than normal. This correlation is 
statistically significant (p <0.05), could be 
seen in table 10.  
 
 




AMH Category Total p r 
1.5 - 4 >4   
N % N % N %   
10 – 20  
20 – 30  






9 12.9 18 25.7 27 38,6 





The mean of pretreatment AMH level 
was 7.6957 ± 0.6001 ng/ml and the mean of 
post treatment AMH level was 7.5914 ± 
0.57678 ng/ml. There was a significant 
difference (p <0.001) and the mean AMH 
level in all patients was 0.10429. The mean 
AMH level before metformin therapy in 
obese PCOS patients was 7.9231 ± 0.51359 
ng/ml while the mean AMH level before 
therapy in PCOS nonobese patients was 
7.0389 ± 0.23549 ng/ml. It was concluded 
that the difference in the mean AMH level 
before metformin therapy in the obese and 
nonobese group was 0.88419. When we 
calculated the mean AMH levels after 
metformin therapy in the obese PCOS group, 
we obtained 7.8731 ± 0.43572 ng/ml and the 
mean AMH level after therapy in nonobese 
PCOS patients was 7.0111 ± 0.26544 ng/ml. 
The differences in the mean AMH levels after 
metformin therapy in the obese and nonobese 






There was significant decrease namely 
0.05 (p = 0.022) of the mean AMH level after 
metformin therapy in 52 obese patients, 
which showed that metformin was able to 
reduce AMH levels in obese PCOS patients 
effectively in the majority of cases. Statistical 
calculations on nonobese PCOS patients 
showed that the mean decrease of AMH level 
after metformin therapy in 18 samples of 
nonobese group was 0.02778 which showed 
that metformin was able to reduce the AMH 
levels in nonobese PCOS patients but was not 
statistically significant.   
               Velazquez, et al. studied 26 obese women 
treated with metformin 1500 mg/day for 8 
weeks and concluded that metformin reduced 
serum insulin concentration and free serum 
testosterone significantly by 52%. Three of 
the 26 sufferers even got pregnant.  13 
               Nestler and Jacubowicz (1996) in a 
placebo-controlled trial that used metformin 
1500 mg/day for 4-8 weeks in 24 obese 
PCOS women obtained similar results in a 
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decrease in circulating insulin levels in 
women treated with metformin. The study 
also found a reduction in LH stimulated by 
GnRH and reduced ovarian androgen 
production and also free testosterone serum 
concentration by 44%. Whereas eight other 
studies using metformin showed improved 
menstruation or reduction of androgens in 
women with PCOS.  13 
     Metformin played a direct role in PCOS 
by ovarian sensitization. In a study conducted 
by Falbo, et al. it was said that AMH levels 
were significantly higher in PCOS patients 
compared to healthy controls. A possible 
hypothesis in these patients was that AMH is 
produced as a result of an increase in the 
number of ovarian follicles.  13 
      Falbo, et al. said that in PCOS patients 
who were given metformin therapy, there 
were significant changes in AMH levels. 
Several studies had shown that metformin 
can improve insulin resistance and ovarian 
morphology. 13 A retrospective study by 
Piltonen, et al. showed that AMH levels, 
antral follicle counts, and ovarian volume 




AMH levels after metformin therapy 
significantly decreased compared to AMH 
levels before therapy in overall PCOS 
patients. AMH levels after metformin 
therapy also decreased significantly in obese 
PCOS patients, but not significantly in 
nonobese PCOS patients. There is a 
significant relationship between the antral 
follicles count and AMH level. The higher 
AMH levels were, the number of antral 
follicles would be 1.5 times more than 
normal.  
     Further research was recommended to 
find out the optimal time of metformin 
therapy which could reduce AMH levels to 
reach normal levels and examined the effects 
of metformin therapy that could improve 
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